Pacific Point Advisors LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Pacific Point Advisors LLC bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 875 shares of the medical research company's stock, valued at approximately $455,000.

A number of other institutional investors have also modified their holdings of TMO. LaFleur & Godfrey LLC increased its holdings in shares of Thermo Fisher Scientific by 9.1% during the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock valued at $15,486,000 after purchasing an additional 2,488 shares during the period. Fort Washington Investment Advisors Inc. OH lifted its holdings in shares of Thermo Fisher Scientific by 11.0% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 5,109 shares of the medical research company's stock valued at $2,658,000 after purchasing an additional 507 shares during the last quarter. Beaumont Financial Advisors LLC increased its position in shares of Thermo Fisher Scientific by 24.8% in the fourth quarter. Beaumont Financial Advisors LLC now owns 2,021 shares of the medical research company's stock worth $1,052,000 after acquiring an additional 402 shares in the last quarter. XML Financial LLC grew its holdings in shares of Thermo Fisher Scientific by 49.6% during the fourth quarter. XML Financial LLC now owns 863 shares of the medical research company's stock valued at $449,000 after buying an additional 286 shares in the last quarter. Finally, Advisory Alpha LLC grew its stake in shares of Thermo Fisher Scientific by 12.5% in the 4th quarter. Advisory Alpha LLC now owns 1,432 shares of the medical research company's stock valued at $745,000 after buying an additional 159 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TMO. Royal Bank of Canada cut their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Scotiabank lowered their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. Citigroup reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Morgan Stanley upped their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $607.43.

Thermo Fisher Scientific Stock Up 0.2%

TMO stock traded up $0.65 during midday trading on Wednesday, reaching $404.20. 839,145 shares of the company's stock traded hands, compared to its average volume of 1,868,905. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The company has a market cap of $152.58 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm's fifty day moving average price is $437.74 and its 200-day moving average price is $502.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter last year, the company posted $5.11 earnings per share. The firm's quarterly revenue was up .2% compared to the same quarter last year. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,075 shares of company stock worth $7,305,942 over the last ninety days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.